Overview

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Summary

Trial N01395 is to evaluate the reduction of nonpsychotic behavioral side effects in subjects with Epilepsy who switched to BRV 200 mg/day after discontinuing LEV due to such side effects; as well as the efficacy, safety and tolerability of BRV. No statistical hypothesis testing will be performed.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Pharma SA

Treatments:

Brivaracetam
Etiracetam
Piracetam